Together, our findings support the hypothesis that MC1R/cAMP signals coupled with ATR-dependent events regulate melanocytic NER, reduce cisplatin-induced mutagenesis and raise the possibility that pharmacologic cAMP activation may be a useful strategy for enhanced melanocyte genomic stability to reduce secondary melanoma risk in patients treated with platinum-containing chemotherapeutics. This evidence concerns the gene ATR and melanoma.